Sign Out
Click on icon to see table/diagram/imageNeonates <7 days: Most pre-term neonates <7 days of age (gestational age <34 weeks) have lower systemic linezolid clearance values and larger AUC values that many full-term neonates and older infants. These neonates should be initiated with a dosing regimen of 10 mg/kg q12h. Consideration may be given to the use of 10 mg/kg q8h regimen in neonates with a sub-optimal clinical response. All neonatal patient should receive 10 mg/kg q8h by 7 days of life.
Adult patients with infection due to MRSA should be treated with LINEZOLID 600 mg q12h.
LINEZOLID should be administered by intravenous infusion over a period of 30 to 120 minutes.
No dose adjustment is necessary when switching from intravenous to oral administration. Patients whose therapy started with LINEZOLID I.V. Injection may be switched to either Linezolid Tablets or Oral Suspension at the discretion of the physician, when clinically indicated.
